Brinckerhoff Quoted on ACLU/Myriad Decision

14 June 2013 Financial Times News

Financial Times

Partner Courtenay Brinckerhoff was quoted in a June 14, 2013 Financial Times article titled, “Agricultural groups explore impact of ruling.” The article discussed the implications of the Supreme Court’s June 13, 2013 decision in the “ACLU/Myriad” gene patenting case (12-398, Association for Molecular Pathology v. Myriad Genetics, Inc.) on agricultural biotech companies. Manufacturers of GM seeds and altered plant material had thought themselves beyond the reach of Myriad, because they “believe their products have been changed enough to fall outside the judges’ definition of ‘products of nature.’” However, Ms. Brinckerhoff cautioned that, in light of Myriad and other recent decisions, companies should be proactive in reviewing patent portfolios as well as their legal position, and be prepared to take on new competitors. She stated, “It’s never crystal clear until you have the actual same facts decided.”

Related Services


Do You Know What IMMEX Stands For?
16 July 2019
Dashboard Insights
Does The U.S. Need STRONGER Patents?
16 July 2019
PTAB Trial Insights
California Establishes Fund to Combat Wildfire Threats
15 July 2019
Renewable Energy Outlook
There’s No Place Like Home – But Is That a Reasonable Accommodation?
15 July 2019
Labor & Employment Law Perspectives
Review of 2020 Medicare Changes for Telehealth
11 December 2019
Member Call
2019 NDI Executive Exchange
14-15 November 2019
Chicago, IL
MAGI’s Clinical Research Conference
29 October 2019
Las Vegas, NV
Association for Corporate Counsel Annual Meeting 2019
27-30 October 2019
Phoenix, AZ